Article
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.
The Lancet. Oncology - 1 Feb 2026
Zhang Liang, Zhang Xiqin, Wu Lin, Xing Wenqun, Liu Chunling, Zhang Peng, Chen Kai, Shi Jianhua, Xu Shidong, Zhang Xiaodong, Dong Xiaorong, Fang Haohui, Yu Xinmin, Gao Yang, Li Gaofeng, Chen Zhenming, Fan Shaonan, Zhang Xiaoqing, Cheng Ying
Abstract excerpt
BACKGROUND: Patients with resectable non-small-cell lung cancer (NSCLC), particularly those with EGFR mutations, face a high risk of recurrence and mortality post-surgery. Aumolertinib, a third-generation EGFR tyrosine-kinase inhibitor, is approved in China for adjuvant treatment in patients with NSCLC harbouring EGFR with an exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation. The ARTS study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.